Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ray Kim

Showing results (31-40 of 269) with videos related to

Pageof 27
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2011
Surveillance for hepatocellular carcinoma in patients with cirrhosisJu Dong Yang, W Ray Kim
Clinical Liver Disease|April 17, 2019
Epidemiology of Hepatitis B Virus Infection in the United StatesBo Hyun Kim, W Ray Kim
Gastroenterology|August 26, 2010
Rifaximin in hepatic encephalopathy: is an ounce of prevention worth a pretty penny?Michael D Leise, W Ray Kim
Clinics in Liver Disease|October 5, 2002
Medical and economic impact of autoimmune hepatitisJayant A Talwalkar, W Ray Kim
Applied Health Economics and Health Policy|January 19, 2013
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH modelPhil McEwan, Ray Kim, Yong Yuan
Clinics in Liver Disease|January 20, 2009
The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measurePatrick S Kamath, W Ray Kim
Seminars in Liver Disease|May 13, 2016
Epidemiology and Healthcare Burden of Acute-on-Chronic Liver FailureAlina M Allen, W Ray Kim
Current Opinion in Gastroenterology|March 13, 2010
Organ allocation for chronic liver disease: model for end-stage liver disease and beyondSumeet K Asrani, W Ray Kim
Clinics in Liver Disease|October 29, 2011
Model for end-stage liver disease: end of the first decadeSumeet K Asrani, W Ray Kim
Gastroenterology|February 5, 2008
Hepatic vein pressure gradient >10 mm Hg: prognostic or reflective?W Ray Kim, Patrick S Kamath
Pageof 27

Showing results (31-40 of 269) with videos related to

Sort By:
Pageof 27
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2011
Surveillance for hepatocellular carcinoma in patients with cirrhosisJu Dong Yang, W Ray Kim
Clinical Liver Disease|April 17, 2019
Epidemiology of Hepatitis B Virus Infection in the United StatesBo Hyun Kim, W Ray Kim
Gastroenterology|August 26, 2010
Rifaximin in hepatic encephalopathy: is an ounce of prevention worth a pretty penny?Michael D Leise, W Ray Kim
Clinics in Liver Disease|October 5, 2002
Medical and economic impact of autoimmune hepatitisJayant A Talwalkar, W Ray Kim
Applied Health Economics and Health Policy|January 19, 2013
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH modelPhil McEwan, Ray Kim, Yong Yuan
Clinics in Liver Disease|January 20, 2009
The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measurePatrick S Kamath, W Ray Kim
Seminars in Liver Disease|May 13, 2016
Epidemiology and Healthcare Burden of Acute-on-Chronic Liver FailureAlina M Allen, W Ray Kim
Current Opinion in Gastroenterology|March 13, 2010
Organ allocation for chronic liver disease: model for end-stage liver disease and beyondSumeet K Asrani, W Ray Kim
Clinics in Liver Disease|October 29, 2011
Model for end-stage liver disease: end of the first decadeSumeet K Asrani, W Ray Kim
Gastroenterology|February 5, 2008
Hepatic vein pressure gradient >10 mm Hg: prognostic or reflective?W Ray Kim, Patrick S Kamath
Pageof 27